Ribonucleoprotein Vaccines

Ribonucleoproteins are macromolecules especially difficult to produce and need a special engineering to become highly effective as therapeutic cancer vaccines.

Telomium has a unique knowledge in ribonucleoprotein production and has developed proprietary new technologies to break immune tolerance with ribonucleoproteins against a variety of cancer targets or other pathologies, surpassing all current vaccine technologies:
mRNA vaccines, Viral vaccines, DNA vaccines, Protein/peptides vaccines, DC vaccines...

For background knowledge, read first
 our introduction on Cancer Immunotherapy


Ribonucleoproteins Break Immune Tolerance

Ribonucleoproteins are self-macromolecules complexes that are often mistakenly taken for virus by the immune system and become targets in various autoimmune diseases.


Ribonucleoproteins released outside cells are interpreted by the immune system as a virus escaping the classical immune response, thus requiring a more profound and diverse immune response.

Ribonucleoproteins are protein-RNA complexes delivering a temporospatially coordinated activation of a danger signal (by their RNA part) and presentation of the antigen (by their protein part) in the same phagosome, therefore more efficiently mimicking a viral infection, that any other vaccine technologies (even mRNA or viral vectors).

The alarming signal provided by released ribonucleoproteins is so high that the immune system 
now attacks any cells containing the ribonucleoprotein, even if the ribonucleoprotein is a part of the self. This breaks immune tolerance.

Ribonucleoproteins have the unique ability to induce the dual antigen receptor/Toll-like receptor signaling in B cells that diversifies the T cell response to novel epitopes, a key feature unmet by any other vaccine technologies (mRNA, DNA, viral vectors, peptide, proteins…).

The dual BCR/TLR signaling induced by the ribonucleoprotein in the endosomes of B cells transforms B cells into prominent antigen-presenting cells (APC), now delivering unique activation signals to T cells (unreached by any other APCs, even dendritic cells).

B cells activated by ribonucleoproteins antigens diversify the T cell response and break tolerance by promoting epitope spreading to untolerized epitopes.

Ribonucleoproteins can therefore be developed as highly potent "vaccines" to reprogram the immune system and make it attack a specific part of the self. (ex: telomerase in cancer).